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Gleason Score (GS) < 7; the mean of iPSA was 18 ng/mL; the 
rate of clinical positive nodes was 1%. The ADT was 
prescribed to 69% of patients in neoadjuvant setting, 65% in 
concomitant setting and 34% in adjuvant setting. The mean 
follow-up was 81 months.  
 
Results: The prognostic factors resulted statistically 
significant for all groups of patients at both, univariate and 
multivariate analysis, were the GS and the iPSA. In 
intermediate and high/very-high risk patients at multivariate 
analysis the prognostic factors for CSOS were: GS (p=0.001), 
positive lymph nodes on CT scan (p=0.05) and rectal 
preparation during the treatment (p=0.005); for the BDFS 
were: GS (p=0.008), patient risk classification (p=0.037), 
positive lymph nodes on CT scan (p=0.004), iPSA (p=0.001) 
and rectal/bladder preparation during the radiation 
treatment (p=0.001); for the CDFS were: number of positive 
core on biopsy (p=0.003), GS (p=0.0003), positive lymph 
nodes on CT scan (p=0.015), iPSA (p=0.0056) and RT dose 
(p=0.001). In high/very-high risk patient group at 
multivariate analysis the prognostic factors for CSOS were: 
biopsic Gleason Score, clinical/radiological stage, RT dose; 
for BDFS were: biopsic Gleason Score, adjuvant ADT, 
clinical/radiological stage, iPSA and RT dose>77.7 Gy; for 
CDFS were: biopsic Gleason Score, clinical/radiological stage, 
iPSA and RT dose>77.7 Gy. 
 
Conclusion: Our results confirm several prognostic factors 
already described by literature, adding a new prognostic 
factor represented by the rectal/bladder preparation, 
generally known for its effect on toxicity but not yet on 
outcome. We believe that in the future a new nomogram 
should include also some therapeutic variables (as RT dose, 
RT technique and ADT), to help clinicians in decision-making. 
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Purpose or Objective: We aim to evaluate the biochemical 
failure free survival (BFFS) and morbidity in high risk prostate 
cancer patients treated with long term androgen deprivation 
therapy (ADT) and hypofractionated Simultaneous Integrated 
Boost (SIB) IMRT. Recent advances in techniques enable us to 
deliver a higher dose of radiation to the prostate with limited 
dose to the adjacent rectum and bladder. Earlier studies 
have estimated prostate cancer to have low α/β of 1.5. Thus 
hypofractionated schedules in theory should confer better 
local control and cancer specific survival (CSS). Due to the 
long natural history of prostate cancer it becomes imperative 
to reduce rectal and bladder morbidity. Also BFFS has shown 
to be a predictor of CSS. Most of the studies with whole 
pelvic RT and long term ADT have used conventional 
fractionation schedules. Data on the benefit of 
hypofractionated SIB IMRT with long term ADT is limited.  
 
Material and Methods: Retrospective analysis of 100 high risk 
prostate cancer patients treated between 2010-2012. All 
patients received SIB IMRT with 70Gy in 28 fractions to the 
prostate and seminal vesicles (if involved ) and 50.4 Gy in 28 
fractions to the pelvic nodal stations with neoadjuvant 
hormonal therapy for a duration of 3-6 months prior to 
radiation and adjuvant hormonal therapy for a duration of 
24-36 months. They were followed up with serial PSA values 
and clinical examination. Biochemical failure was defined as 
serum PSA >nadir + 2 (ASTRO Phoenix definition). Acute 
rectal and bladder toxicity was scored with the RTOG toxicity 
criteria. Chronic rectal toxicity (proctitis) and chronic 
bladder toxicity (cystitis ) were assessed using the CTCAE 4.0. 
Patients without biochemical failure were censored at last 
follow-up/last PSA check or death. BFFS was calculated by 
the Kaplan-Meier method. 
 
Results: At a median follow up of 45 months (20-87 months ), 
there were 13 cases of biochemical failure (13 %) . 5 year 
BFFS was 78.6% .There was no Grade 3 or 4 acute rectal or 
bladder toxicity . Chronic toxicity has been listed in the table 
below. Urethral stricture developed in 7 patients, of whom 6 
had prior TURP showing significant correlation 
(6/15,p<0.001). 
 
 
 
 Grade 2  Grade 3  Grade 4  
Proctitis  12  2 0 
Cystitis  7 0 0 
 
Conclusion: This study therefore concludes that long term 
ADT and SIB IMRT provides a feasible alternative to 
conventional radiation therapy with good biochemical control 
and acceptable toxicity. Longer follow up of these patients 
would provide data on cancer specific survival and late 
morbidity.  
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Purpose or Objective: A status of disease with a limited 
number of distant lesions and a controlled primitive tumor is 
recently defined as oligo-recurrence: this group of patients is 
more favorable than the other with a high number of 
metastases and, in prostate cancer, often is represented by a 
single node.The objective of this retrospective study was to 
evaluate the acute and late toxicity rates, in salvage 
stereotactic body radiation therapy (SBRT) as a treatment 
modality in nodes oligo-recurrence, from prostate cancer. 
 
Material and Methods: Between February 2013 and March 
2015, 21 patients, for a total of 29 isolated lymph nodes from 
prostate cancer, were treated with SBRT, delivered with 
Truebeam Stx (Varian®), at UPMC San Pietro FBF 
radiotherapy center of Rome.The median age at primitive 
diagnoses was 65 (range 50-74) years. For the primary 
treatment, radical prostatectomy and postoperative 
irradiation, exclusive radiotherapy or prostatectomy was 
performed in 12 (57%) patients, 7 patients (33%) and 2 
patients (10%), respectively. Median previous RT dose was 72 
Gy/35 fractions.Median PSA at the time of recurrence was 
2.04ng/ml.All patients with arising PSA underwent a [11C] 
choline-positron emission tomography before SBRT, in order 
to exclude other sites of disease. The SBRT dose varied from 
27 to 30 Gy, in 1-5 daily fractions, according to the previous 
RT treatment for the primitive lesion or a close organ at risk. 
A daily cone-beam CT and X-ray (BRAINLAB ExacTrac®) scans 
were acquired before each treatment session, for every 
